PMID- 8255102
OWN - NLM
STAT- MEDLINE
DCOM- 19940107
LR  - 20171116
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 7
IP  - 12
DP  - 1993 Dec
TI  - Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with 
      chronic lymphocytic leukemia.
PG  - 2019-25
AB  - We measured the soluble (s) receptors CD23, CD8, CD4, interleukin-2 receptor 
      (IL-2R, CD25), and transferrin receptor (TfR, CD71), in normal serum and in 
      patients with chronic lymphocytic leukemia (CLL) and evaluated them in relation 
      to clinical and biological parameters of the disease, as well as serum 
      immunoglobulin E (IgE). Compared to 31 normal individuals, 42 CLL patients had 
      increased levels of sCD23 (98.4 +/- 127.7 versus 0.9 +/- 0.3 U/ml, p < 0.001), 
      sIL-2R (6080 +/- 7030 versus 1420 +/- 640 pg/ml, p < 0.001), sTfR (12,100 +/- 
      11,250 versus 5000 +/- 1050 ng/ml, p < 0.001), and sCD8 (510 +/- 191 versus 234 
      +/- 89 U/ml, p < 0.001), but normal sCD4 levels. Mean sCD23 levels remained 
      normal in patients with non-Hodgkin's lymphoma (other than small lymphocytic), 
      Hodgkin's disease, hairy cell leukemia, acute lymphoblastic leukemia (ALL), acute 
      myelogenous leukemia (AML), chronic myelogenous leukemia (CML), multiple myeloma, 
      or solid tumors. Advancing Rai clinical stage was associated with a progressive 
      elevation of sCD23 (p < 0.001), while sCD8 (p < 0.05), sIL-2R (p < 0.001), and 
      sTfR (p < 0.005) were highest in stage 2 patients. Discriminant analysis 
      confirmed the value of soluble receptor determinations in the clinical evaluation 
      of CLL patients. sCD23 correlated with sIL-2R (p < 0.001) and sTfR (p < 0.05) but 
      not with sCD4 or sCD8, and displayed an inverse relationship with serum IgE (NS) 
      and total gamma-globulin (p < 0.05). sIL-2R correlated with sCD23 (p < 0.001), 
      sTfR (p < 0.001), sCD4 (p < 0.01), and sCD8 (p < 0.01). The lymphocyte count 
      correlated with serum lactate dehydrogenase (LDH) (p < 0.05), sCD23 (p < 0.001) 
      and sIL-2R (p < 0.01) but not sTfR, sCD8, or sCD4. Chemotherapy produced 
      consistent reductions of sCD23 levels in two responding patients. We conclude 
      that: (i) sCD23 is considerably elevated in CLL, correlates with the tumor mass 
      and clinical stage, and could be helpful in monitoring these patients; and (ii) 
      sIL-2R, sCD8, and sTfR levels are less specifically increased and could be 
      influenced by other factors such as immune activation and erythropoiesis.
FAU - Beguin, Y
AU  - Beguin Y
AD  - Department of Medicine, University of Liege, Belgium.
FAU - Lampertz, S
AU  - Lampertz S
FAU - De Groote, D
AU  - De Groote D
FAU - Igot, D
AU  - Igot D
FAU - Malaise, M
AU  - Malaise M
FAU - Fillet, G
AU  - Fillet G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, B-Lymphocyte)
RN  - 0 (CD4 Antigens)
RN  - 0 (CD71 antigen)
RN  - 0 (CD8 Antigens)
RN  - 0 (Receptors, Cell Surface)
RN  - 0 (Receptors, IgE)
RN  - 0 (Receptors, Interleukin-2)
RN  - 0 (Receptors, Transferrin)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Aged
MH  - Antigens, CD/blood
MH  - Antigens, Differentiation, B-Lymphocyte/blood
MH  - CD4 Antigens/blood
MH  - CD8 Antigens/blood
MH  - Discriminant Analysis
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*blood/immunology
MH  - Leukocyte Count
MH  - Lymphocytes
MH  - Male
MH  - Middle Aged
MH  - Receptors, Cell Surface/*metabolism
MH  - Receptors, IgE/*metabolism
MH  - Receptors, Interleukin-2/metabolism
MH  - Receptors, Transferrin/metabolism
MH  - Solubility
EDAT- 1993/12/01 00:00
MHDA- 1993/12/01 00:01
CRDT- 1993/12/01 00:00
PHST- 1993/12/01 00:00 [pubmed]
PHST- 1993/12/01 00:01 [medline]
PHST- 1993/12/01 00:00 [entrez]
PST - ppublish
SO  - Leukemia. 1993 Dec;7(12):2019-25.